Peer-reviewed veterinary case report
New antibody treatment shows promise against canine distemper virus
By Shi, Pengfei et al.·Published in Veterinary microbiology·2025·College of Veterinary Medicine, China·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Whole-canine neutralizing antibodies generated by single B cell antibody technology elicit therapeutic protection against canine distemper virus infection.
- Species:
- dog
Plain-English summary
A study found that two specific antibodies, D16 and F53, showed promise in treating dogs infected with the canine distemper virus (CDV), a serious and often fatal disease. While vaccination is the main way to prevent CDV, some dogs still get sick due to vaccine failures, and there are currently no effective treatments for the infection. The researchers developed these antibodies using a special technique and tested them on dogs exposed to a lethal dose of the virus. The results suggest that the D16 antibody could potentially help treat dogs suffering from CDV.
People also search for: dog distemper treatment · canine distemper virus symptoms · dog vaccination failure treatment
Abstract
Canine distemper virus (CDV) causes a highly contagious and fatal disease in domestic and wild carnivores. Currently, vaccination is the primary method for preventing canine distemper. However, incidents of vaccine immunization failures continue to be reported. There are no specific and effective treatment agents available for canine distemper infection. Neutralizing antibodies offer a potential approach for the treatment of viral diseases. In this study, single B cell antibody technology was applied to obtain whole-canine antibodies against CDV. 7 monoclonal antibodies were screened and showed high binding affinity to CDV hemagglutinin (H) protein, with D16 and F53 exhibited high specificity and neutralizing activity against CDV. Furthermore, D16 exhibited effective therapeutic potential in dogs subjected to lethal dose CDV attacks in vivo. In conclusion, our study offers an alternative approach for acquiring neutralizing antibody and provides a promising new strategy for the treatment of CDV infection.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/39893954/